Cellebrite DI (CLBT) Common Equity (2020 - 2026)

Cellebrite DI has reported Common Equity for 7 years, with the latest figure at $538.1 million in Q2 2026.

• On a quarterly basis, Common Equity rose 31.75% year-over-year to $538.1 million in Q2 2026; TTM through Jun 2026 was $538.1 million, a 31.75% increase from a year earlier, with the FY2025 full-year figure at $484.3 million, up 44.13% from the prior year.
• Common Equity was $538.1 million for Q2 2026 at Cellebrite DI, up from $510.5 million in the prior quarter.
• The five-year high for Common Equity was $538.1 million in Q2 2026, with the low at -$40.2 million in Q2 2024.
• Average Common Equity over 5 years is $199.7 million, with a median of $66.7 million recorded in 2022.
• The sharpest annual moves came in 2024 and 2025: Common Equity tumbled 328.75% in 2024, then surged 1461.09% in 2025.
• Over 5 years, Common Equity stood at $73.9 million in 2022, then plunged by 53.68% to $34.2 million in 2023, then jumped by 882.17% to $336.0 million in 2024, then jumped by 44.13% to $484.3 million in 2025, then increased by 11.1% to $538.1 million in 2026.
• The last three Common Equity figures came in at $538.1 million (Q2 2026), $510.5 million (Q1 2026), and $484.3 million (Q4 2025), per Business Quant data.